Krystal Biotech, Inc. (KRYS) shares soared 4.2% in the last trading session to close at $143.67. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.3% gain over the past four weeks.The stock price gain was observed after Krystal Biotech initiated dosing patients in its phase III IOLITE study of KB803 eye drops for DEB-related corneal damage. As a next-generation version of its approved gene therapy, Vyjuvek, KB803 targets a rare ...